Journal
ONCOGENE
Volume 34, Issue 43, Pages 5411-5417Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2015.5
Keywords
-
Funding
- American Society of Clinical Oncology Young Investigator Award
- NIH K12 grant
- NIH R01 grant [1-R01 CA1633793-01]
- Cancer Prevention Institute of Texas [RP120108]
- Prostate Cancer Foundation Challenge Grant in Immunology
- American Association for Cancer Research/Cancer Research Institute/Stand-Up-To-Cancer Dream Team grant
Ask authors/readers for more resources
Targeting a T-cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), which need to be recognized and managed with immunosuppressive agents. To date, the majority of our knowledge regarding ipilimumab-associated side effects is based upon clinical studies in melanoma. Here we provide a review of ipilimumab-induced irAEs and our experience in a cohort of 44 patients with prostate cancer who were treated at the MD Anderson Cancer Center on two different clinical trial protocols.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available